KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Taxes Dividends payables Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Pfizer (PFE) Liabilities from Discontinued Operations (2018 - 2019)

Pfizer (PFE) has disclosed Liabilities from Discontinued Operations for 6 consecutive years, with 2413000000.0 as the latest value for Q4 2019.

Quarterly Liabilities from Discontinued Operations rose 27.67% to 2413000000.0 in Q4 2019 from the year-ago period, while the trailing twelve-month figure was 2413000000.0 through Dec 2019, up 27.67% year-over-year, with the annual reading at 2413000000.0 for FY2019, 27.67% up from the prior year.
Liabilities from Discontinued Operations for Q4 2019 was 2413000000.0 at Pfizer, up from 2009000000.0 in the prior quarter.
The five-year high for Liabilities from Discontinued Operations was 2413000000.0 in Q4 2019, with the low at 1890000000.0 in Q4 2018.